Galapagos signs two new drug discovery collaborations with Ono Pharmaceutical

    Mechelen, Belgium  and Osaka,  Japan; 16  April 2007  - Galapagos  NV
(Euronext & LSE: GLPG) announced today that its BioFocus DPI  service
division has signed  two new collaborations  with Ono  Pharmaceutical
Company Ltd.  (Tokyo:  OSA).    These  collaborations  build  on  the
successful relationship between Ono  and DPI, which  began in 2004.
Under the first collaboration announced today, BioFocus DPI will  use
selected compounds  from  its  SoftFocus and  other  synthetic  small
molecule collections to perform  high throughput screening for  Ono's
drug discovery program.   In the  second collaboration, BioFocus  DPI
will  apply  its  medicinal  and  computational  chemistry  and  ADME
profiling expertise in multiple medicinal chemistry projects for Ono.

"We are pleased  with the new  contracts with Ono  that build on  the
longstanding relationship between  Ono and  DPI.   The new  contracts
show  the  benefit  of  building  a  global  drug  discovery  service
business.  We combine expertise from our acquired companies Discovery
Partners International, BioFocus as  well as Inpharmatica,  realizing
the synergy in bringing these activities together," added Onno van de
Stolpe, Chief Executive Officer of Galapagos.

"We  are  dedicated  to  creating  innovative  medicines,"  said  Dr.
Daikichi Fukushima,  Managing  Director, Ono.  "Accordingly,  we  are
enthusiastic about extending  the relationship with  BioFocus DPI,  a
leading company in drug discovery,  so that we can continue  creating
novel drug candidates."

About Galapagos
Galapagos (Euronext Brussels, GLPG; Euronext Amsterdam, GLPGA; London
AiM: GLPG) is a drug discovery company with clinical and pre-clinical
programs in bone and joint diseases, cachexia, and menopausal hot
flashes.  Its division BioFocus DPI offers a full suite of
target-to-drug discovery products and services to pharmaceutical and
biotech companies, encompassing target discovery and validation,
screening and drug discovery through to delivery of pre-clinical
candidates.  BioFocus DPI also provides adenoviral reagents for rapid
identification and validation of novel drug targets, compound
libraries for drug screening as well as chemogenomics and ADMET[1]
database products to select targets and compounds.  Galapagos
currently employs 450 people and operates facilities in eight
countries, with global headquarters in Mechelen, Belgium.  More
information about Galapagos and BioFocus DPI can be found at
www.glpg.com.

CONTACT
Galapagos NV
Onno van de Stolpe, CEO
Tel: [phone]
[e-mail]

This  release  may  contain  forward-looking  statements,  including,
without  limitation,  statements  containing  the  words  "believes,"
"anticipates," "expects," "intends,"  "plans," "seeks,"  "estimates,"
"may," "will,"  "could," "stands  to," and  "continues," as  well  as
similar expressions.   Such  forward-looking statements  may  involve
known and unknown risks, uncertainties and other factors which  might
cause  the  actual  results,  financial  condition,  performance   or
achievements of  Galapagos, or  industry  results, to  be  materially
different from any historic or future results, financial  conditions,
performance  or   achievements   expressed   or   implied   by   such
forward-looking statements.  Given these uncertainties, the reader is
advised not  to  place any  undue  reliance on  such  forward-looking
statements.  These  forward-looking statements speak  only as of  the
date of publication of this document.  Galapagos expressly  disclaims
any obligation to update any such forward-looking statements in  this
document to  reflect  any  change in  its  expectations  with  regard
thereto or any change in events, conditions or circumstances on which
any such statement is based, unless required by law or regulation.

[1] ADMET is the acronym for Absorption, Distribution, Metabolism,
Excretion, and Toxicity: Meeting parameters against these five
criteria is critical to the success of a pharmaceutical compound as a
drug.






Copyright © Hugin ASA 2007. All rights reserved.